IL159015A0 - Polypeptides, their preparation and use - Google Patents
Polypeptides, their preparation and useInfo
- Publication number
- IL159015A0 IL159015A0 IL15901501A IL15901501A IL159015A0 IL 159015 A0 IL159015 A0 IL 159015A0 IL 15901501 A IL15901501 A IL 15901501A IL 15901501 A IL15901501 A IL 15901501A IL 159015 A0 IL159015 A0 IL 159015A0
- Authority
- IL
- Israel
- Prior art keywords
- polypeptides
- preparation
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29357401P | 2001-05-25 | 2001-05-25 | |
US29869801P | 2001-06-15 | 2001-06-15 | |
US30227701P | 2001-06-29 | 2001-06-29 | |
US30545601P | 2001-07-13 | 2001-07-13 | |
PCT/IB2001/001715 WO2002094864A2 (fr) | 2001-05-25 | 2001-08-06 | Adnc et proteines humaines, ainsi que leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
IL159015A0 true IL159015A0 (en) | 2004-05-12 |
Family
ID=27501598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15901501A IL159015A0 (en) | 2001-05-25 | 2001-08-06 | Polypeptides, their preparation and use |
Country Status (7)
Country | Link |
---|---|
US (10) | US7074901B2 (fr) |
EP (1) | EP1390497A2 (fr) |
JP (1) | JP2005508141A (fr) |
AU (1) | AU2001286171B2 (fr) |
CA (1) | CA2448253A1 (fr) |
IL (1) | IL159015A0 (fr) |
WO (1) | WO2002094864A2 (fr) |
Families Citing this family (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1489097E (pt) | 1994-01-11 | 2012-01-04 | Dyax Corp | Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos |
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
US6494879B2 (en) | 1998-10-15 | 2002-12-17 | Scimed Life Systems, Inc. | Treating urinary retention |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20050271701A1 (en) * | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20160287708A9 (en) * | 2000-03-15 | 2016-10-06 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US7317075B2 (en) * | 2000-07-20 | 2008-01-08 | Genentech, Inc. | PRO21384 polypeptides |
US20030100723A1 (en) * | 2000-07-26 | 2003-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
DE10054055A1 (de) | 2000-10-31 | 2002-05-23 | Nmi Univ Tuebingen | Verfahren zur Analyse von Proteinen |
US7054758B2 (en) * | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
US20070015144A9 (en) * | 2001-05-25 | 2007-01-18 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
CA2466298A1 (fr) * | 2001-11-30 | 2003-06-05 | Applied Research Systems Ars Holding N.V. | Procedes pour augmenter les niveaux d'expression de proteines |
US7618788B2 (en) * | 2002-05-10 | 2009-11-17 | Millipore Corporation | Proteome epitope tags and methods of use thereof in protein modification analysis |
CA2490399C (fr) * | 2002-06-19 | 2015-10-06 | Raven Biotechnologies, Inc. | Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible |
US20040049484A1 (en) * | 2002-09-11 | 2004-03-11 | Hamano Life Science Research Foundation | Method and apparatus for separating and extracting information on physiological functions |
CA2514873C (fr) | 2002-12-13 | 2012-01-03 | David Waisman | Compositions et methodes d'inhibition de la croissance des tumeurs et des metastases |
ES2321297T3 (es) * | 2003-01-08 | 2009-06-04 | Novartis Vaccines And Diagnostics, Inc. | Composiciones acuosas estabilizadas que comprenden inhibidor de la via del factor tisular (ivft) o variante del inhibidor de la via del factor tisular. |
ATE490321T1 (de) | 2003-01-17 | 2010-12-15 | Max Planck Gesellschaft | Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung |
NZ537089A (en) * | 2003-02-24 | 2007-07-27 | Morinaga Milk Industry Co Ltd | Interleukin 6 production inhibitor |
EP1616184B2 (fr) * | 2003-03-27 | 2018-05-30 | Children's Hospital Medical Center | Procede et trousse permettant de detecter l'apparition precoce de lesions de cellules tubulaires renales |
US7134459B2 (en) * | 2003-06-12 | 2006-11-14 | Symyx Technologies, Inc. | Methods and apparatus for mixing powdered samples |
PL2520654T3 (pl) | 2003-08-26 | 2017-08-31 | The Regents Of The University Of Colorado, A Body Corporate | Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych |
EP1519194A1 (fr) | 2003-09-24 | 2005-03-30 | Roche Diagnostics GmbH | L'utilisation de GFAP pour identifier une hémorragie intracérébrale |
AU2004275649A1 (en) * | 2003-09-30 | 2005-04-07 | Snow Brand Milk Products Co., Ltd. | Agent for promoting osteogenesis and/or inhibiting bone resorption |
CN101018808B (zh) | 2003-11-12 | 2014-07-23 | 科罗拉多州大学评议会 | 调节肿瘤坏死因子α的组合物和方法 |
US7332179B2 (en) | 2003-12-12 | 2008-02-19 | Kimberly-Clark Worldwide, Inc. | Tissue products comprising a cleansing composition |
EP1730286A4 (fr) * | 2004-03-04 | 2007-09-05 | Massachusetts Inst Technology | Traitement anticancereux a base d'adn |
AU2004317548A1 (en) * | 2004-03-25 | 2005-10-06 | Centocor, Inc. | Use of EMMPRIN antagonists for the treatment of diseases associated with excessive angiogenesis |
EP1614755A1 (fr) * | 2004-07-07 | 2006-01-11 | ARTEMIS Pharmaceuticals GmbH | Transgénèse ciblée de cassettes d'expression de shh RNA (Short hairpin RNA) par échange de cassette moyennant une récombinase |
EP1771470B1 (fr) * | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Polypeptides du recepteur actrii, procedes et compositions correspondants |
IL163453A0 (en) * | 2004-08-10 | 2009-02-11 | Yeda Res & Dev | Enzyme inhibitor in leukemia |
US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
US9145582B2 (en) * | 2004-09-22 | 2015-09-29 | The Trustees Of The University Of Pennsylvania | Microarray techniques for nucleic acid expression analyses |
US20060111296A1 (en) | 2004-11-22 | 2006-05-25 | Dyax Corp. | Plasmin-inhibitory therapies |
US8172855B2 (en) | 2004-11-24 | 2012-05-08 | Abdou M S | Devices and methods for inter-vertebral orthopedic device placement |
CA2597945C (fr) | 2005-02-17 | 2016-07-12 | Biogen Idec Ma Inc. | Traitement de troubles neurologiques |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
AU2006244014B2 (en) | 2005-05-10 | 2011-03-17 | Biogen Ma Inc. | Treating and evaluating inflammatory disorders |
US20060265352A1 (en) * | 2005-05-20 | 2006-11-23 | International Business Machines Corporation | Methods and apparatus for information integration in accordance with web services |
CA2611002A1 (fr) * | 2005-06-07 | 2006-12-14 | The Rockefeller University | Stimulation de la proliferation des cellules beta pancreatiques |
US20070031373A1 (en) * | 2005-08-04 | 2007-02-08 | Carlos Lopez | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors |
CN103432568A (zh) | 2005-11-23 | 2013-12-11 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
US8128933B2 (en) * | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
EP2363711A1 (fr) * | 2006-01-27 | 2011-09-07 | Tripath Imaging, Inc. | Méthodes permettant d'identifier des patientes présentant un risque accru d'être atteintes d'un cancer de l'ovaire et compositions associées |
US8273005B2 (en) * | 2006-02-02 | 2012-09-25 | Samy Abdou | Treatment of pain, neurological dysfunction and neoplasms using radiation delivery catheters |
US7855057B2 (en) * | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
US7888044B2 (en) | 2006-04-10 | 2011-02-15 | Trustees Of Boston University | Melanoma biomarker and methods of uses |
RU2451521C2 (ru) * | 2006-06-16 | 2012-05-27 | Онкотерапи Сайенс, Инк. | Sparc-производные антигенные пептиды отторжения опухоли и лекарственные средства, содержащие их |
US20100284933A1 (en) * | 2006-10-16 | 2010-11-11 | Biogen Idec Ma Inc. | Biomarkers of Multiple Sclerosis |
WO2008066691A2 (fr) * | 2006-11-08 | 2008-06-05 | Macrogenics West, Inc. | Tes7, et anticorps se liant à celui-ci |
EA035911B1 (ru) * | 2006-12-18 | 2020-08-31 | Акселерон Фарма Инк. | Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
EP2599495A1 (fr) * | 2007-02-01 | 2013-06-05 | Acceleron Pharma, Inc. | Antagonistes de l'Activine-ActRIIa et leurs utilisations dans le traitement ou la prevention du cancer du sein |
TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
CA2677605C (fr) * | 2007-02-09 | 2016-01-19 | Acceleron Pharma Inc. | Antagonistes de l'activine-actriia et utilisations pour la promotion de la croissance osseuse chez les patients cancereux |
JP5572284B2 (ja) * | 2007-02-27 | 2014-08-13 | Jx日鉱日石エネルギー株式会社 | 冷凍機油および冷凍機用作動流体組成物 |
US20080261298A1 (en) * | 2007-04-23 | 2008-10-23 | Olympus American Inc. | Method and device for the multiplex analysis of cells and tissues |
CA2692171C (fr) | 2007-06-22 | 2019-10-22 | Randolph Watnick | Procedes et utilisations de prosaposine |
WO2009038745A1 (fr) * | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Antagonistes de l'activine-actriia et utilisations pour réduire ou empêcher la sécrétion de fsh |
US8796206B2 (en) * | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
KR20220002710A (ko) * | 2008-06-26 | 2022-01-06 | 악셀레론 파마 인코포레이티드 | 액티빈-actriia 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
EP3804746A1 (fr) * | 2008-06-26 | 2021-04-14 | Acceleron Pharma Inc. | Antagonistes d actriib et utilisations pour augmenter les taux d érythrocytes |
GB0813123D0 (en) * | 2008-07-17 | 2008-08-27 | Symbian Software Ltd | Method of searching |
TWI354789B (en) * | 2008-07-18 | 2011-12-21 | Univ Kaohsiung Medical | Il-8 as biomarker for the detection of urolithiasi |
WO2010011860A1 (fr) | 2008-07-23 | 2010-01-28 | Diabetomics, Llc | Procédé de détection du pré-diabète et du diabète |
LT2340031T (lt) | 2008-08-14 | 2019-08-12 | Acceleron Pharma Inc. | Gdf gaudyklės, skirtos naudoti anemijos gydymui |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
US8138142B2 (en) * | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
US8178488B2 (en) | 2009-06-08 | 2012-05-15 | Acceleron Pharma, Inc. | Methods for increasing thermogenic adipocytes |
CN102656187A (zh) | 2009-06-12 | 2012-09-05 | 阿塞勒隆制药公司 | 截短的actriib-fc融合蛋白 |
CA2769822C (fr) | 2009-08-13 | 2019-02-19 | The Johns Hopkins University | Methodes de modulation de la fonction immunitaire |
CA2779472C (fr) * | 2009-11-03 | 2021-03-16 | Acceleron Pharma Inc. | L'utilisation d'une composition renfermant un polypeptide recepteur d'activine de type iib pour le traitement de steatose hepatique |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
US8764806B2 (en) | 2009-12-07 | 2014-07-01 | Samy Abdou | Devices and methods for minimally invasive spinal stabilization and instrumentation |
AU2010339794B2 (en) | 2009-12-17 | 2016-09-22 | Children's Medical Center Corporation | Saposin-A derived peptides and uses thereof |
JP2013545439A (ja) | 2010-09-17 | 2013-12-26 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 多能性幹細胞の有用性および安全性の特徴決定を行うための機能的ゲノミクスアッセイ |
CA2817008A1 (fr) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Agents de liaison a actriia et leurs utilisations |
WO2012177906A1 (fr) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Dosages et procédés de détermination de l'activité d'un agent thérapeutique chez un sujet |
CA2839917A1 (fr) | 2011-06-24 | 2012-12-27 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, procedes et utilisations de molecules de fusion de l'alpha-1 antitrypsine |
CA2839451A1 (fr) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Procedes et compositions pour le traitement du cancer et d'une maladie auto-immune |
US8845728B1 (en) | 2011-09-23 | 2014-09-30 | Samy Abdou | Spinal fixation devices and methods of use |
WO2013055911A1 (fr) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Biomarqueur znf365/zfp365 pouvant prévoir une réponse anticancéreuse |
EP2780467B1 (fr) | 2011-11-14 | 2018-10-17 | Alfasigma S.p.A. | Dosages et procédés pour la sélection d'un schéma thérapeutique pour un sujet atteint d'une dépression |
US10736935B2 (en) | 2011-12-22 | 2020-08-11 | Children's Medical Center Corporation | Saposin-A derived peptides and uses thereof |
AU2013202648B2 (en) | 2012-01-10 | 2016-05-19 | Konkuk University | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
US20130269537A1 (en) | 2012-04-16 | 2013-10-17 | Eugenio Minvielle | Conditioning system for nutritional substances |
US20130226240A1 (en) | 2012-02-22 | 2013-08-29 | Samy Abdou | Spinous process fixation devices and methods of use |
US20130269538A1 (en) | 2012-04-16 | 2013-10-17 | Eugenio Minvielle | Transformation system for nutritional substances |
US9541536B2 (en) | 2012-04-16 | 2017-01-10 | Eugenio Minvielle | Preservation system for nutritional substances |
US10219531B2 (en) | 2012-04-16 | 2019-03-05 | Iceberg Luxembourg S.A.R.L. | Preservation system for nutritional substances |
WO2013148405A2 (fr) * | 2012-03-27 | 2013-10-03 | Felder Mitchell S | Traitement pour l'athérosclérose |
ES2702278T3 (es) | 2012-04-01 | 2019-02-28 | Technion Res & Dev Foundation | Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión |
US9564064B2 (en) | 2012-04-16 | 2017-02-07 | Eugenio Minvielle | Conditioner with weight sensors for nutritional substances |
US9121840B2 (en) | 2012-04-16 | 2015-09-01 | Eugenio Minvielle | Logistic transport system for nutritional substances |
US9171061B2 (en) | 2012-04-16 | 2015-10-27 | Eugenio Minvielle | Local storage and conditioning systems for nutritional substances |
US8733631B2 (en) | 2012-04-16 | 2014-05-27 | Eugenio Minvielle | Local storage and conditioning systems for nutritional substances |
US9436170B2 (en) | 2012-04-16 | 2016-09-06 | Eugenio Minvielle | Appliances with weight sensors for nutritional substances |
US20140069838A1 (en) | 2012-04-16 | 2014-03-13 | Eugenio Minvielle | Nutritional Substance Label System For Adaptive Conditioning |
US9528972B2 (en) | 2012-04-16 | 2016-12-27 | Eugenio Minvielle | Dynamic recipe control |
US9702858B1 (en) | 2012-04-16 | 2017-07-11 | Iceberg Luxembourg S.A.R.L. | Dynamic recipe control |
US9429920B2 (en) | 2012-04-16 | 2016-08-30 | Eugenio Minvielle | Instructions for conditioning nutritional substances |
US9460633B2 (en) | 2012-04-16 | 2016-10-04 | Eugenio Minvielle | Conditioner with sensors for nutritional substances |
US9414623B2 (en) * | 2012-04-16 | 2016-08-16 | Eugenio Minvielle | Transformation and dynamic identification system for nutritional substances |
US9080997B2 (en) | 2012-04-16 | 2015-07-14 | Eugenio Minvielle | Local storage and conditioning systems for nutritional substances |
US9069340B2 (en) | 2012-04-16 | 2015-06-30 | Eugenio Minvielle | Multi-conditioner control for conditioning nutritional substances |
US9072317B2 (en) | 2012-04-16 | 2015-07-07 | Eugenio Minvielle | Transformation system for nutritional substances |
US9198767B2 (en) | 2012-08-28 | 2015-12-01 | Samy Abdou | Devices and methods for spinal stabilization and instrumentation |
US9320617B2 (en) | 2012-10-22 | 2016-04-26 | Cogent Spine, LLC | Devices and methods for spinal stabilization and instrumentation |
KR20210091358A (ko) | 2012-11-02 | 2021-07-21 | 셀진 코포레이션 | 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도 |
JP6697380B2 (ja) | 2013-06-10 | 2020-05-20 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 多能性幹細胞の有用性および安全性を特徴付けるための初期発生ゲノムアッセイ |
US10790062B2 (en) | 2013-10-08 | 2020-09-29 | Eugenio Minvielle | System for tracking and optimizing health indices |
JP2017506259A (ja) | 2014-02-03 | 2017-03-02 | イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドYissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | 幹細胞を枯渇させるためのカゼインキナーゼi阻害剤の使用 |
EP3134546A4 (fr) | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire |
MX2016016531A (es) | 2014-06-13 | 2017-04-25 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de las ulceras. |
CA2952285A1 (fr) | 2014-06-19 | 2015-12-23 | Memorial Sloan-Kettering Cancer Center | Biomarqueurs de la reponse aux inhibiteurs d'ezh2 |
EP3998273A1 (fr) | 2014-07-17 | 2022-05-18 | The Trustees Of The University Of Pennsylvania | Procédés permettant d'utiliser des exosomes pour surveiller l'état d'un organe transplanté |
USD762081S1 (en) | 2014-07-29 | 2016-07-26 | Eugenio Minvielle | Device for food preservation and preparation |
WO2016057367A1 (fr) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Biomarqueurs à base d'angiopoïétine -2 utilisés pour la prédiction de la réponse de point de contrôle anti-immunitaire |
JP6941561B2 (ja) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 免疫障害を処置するための複数の可変il−2用量レジメン |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
HUE062189T2 (hu) | 2014-12-03 | 2023-09-28 | Celgene Corp | Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére |
AU2016229238B2 (en) | 2015-03-06 | 2022-06-02 | Dana-Farber Cancer Institute, Inc. | PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers |
KR101713421B1 (ko) * | 2015-07-03 | 2017-03-09 | 울산대학교 산학협력단 | 뇌신경질환의 진단 또는 치료용 조성물 |
US10857003B1 (en) | 2015-10-14 | 2020-12-08 | Samy Abdou | Devices and methods for vertebral stabilization |
US10464977B2 (en) * | 2016-04-11 | 2019-11-05 | University Of Maryland, Baltimore | Histatin-5 based synthetic peptides and uses thereof |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018057618A1 (fr) | 2016-09-20 | 2018-03-29 | Dana-Farber Cancer Institute, Inc. | Compositions et méthodes pour l'identification, l'évaluation, la prévention et le traitement de la lma au moyen de biomarqueurs usp10 et de modulateurs |
US10744000B1 (en) | 2016-10-25 | 2020-08-18 | Samy Abdou | Devices and methods for vertebral bone realignment |
US10973648B1 (en) | 2016-10-25 | 2021-04-13 | Samy Abdou | Devices and methods for vertebral bone realignment |
EP3634496A4 (fr) | 2017-06-06 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | Procédés de sensibilisation de cellules cancéreuses à une destruction médiée par des lymphocytes t par modulation de voies moléculaires |
WO2019094578A1 (fr) | 2017-11-09 | 2019-05-16 | Alnylam Pharmaceuticals Inc. | Dosages et procédés de détermination de l'expression du gène lect2 |
US11179248B2 (en) | 2018-10-02 | 2021-11-23 | Samy Abdou | Devices and methods for spinal implantation |
US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
US12018279B2 (en) | 2019-10-18 | 2024-06-25 | The Trustees Of The University Of Pennsylvania | Micro-engineered models of the human eye and methods of use |
CN111161800B (zh) * | 2019-12-30 | 2021-05-07 | 云舟生物科技(广州)有限公司 | 基因载体的序列诊断方法、系统、存储介质及电子设备 |
AR123960A1 (es) | 2020-10-29 | 2023-01-25 | Evelo Biosciences Inc | Composiciones que comprenden componentes de espirulina |
CN112716971B (zh) * | 2021-01-19 | 2022-01-25 | 苏州大学 | lncRNA XR_595534.2在制备治疗或预防慢性疼痛的药物中的应用 |
JP2024509530A (ja) | 2021-03-02 | 2024-03-04 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 赤血球障害を治療する方法 |
EP4074820A1 (fr) | 2021-04-16 | 2022-10-19 | The Trustees of The University of Pennsylvania | Modèles micro-façonnés de l' il humain et procédés d'utilisation |
WO2022251166A2 (fr) | 2021-05-25 | 2022-12-01 | Evelo Biosciences, Inc. | Compositions bactériennes comprenant de l'hémoglobine de soja |
WO2022261183A2 (fr) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux |
WO2023097119A2 (fr) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Méthodes et compositions pour moduler riok2 |
GB202208171D0 (en) | 2022-06-01 | 2022-07-13 | Institute Of Cancer Res | Method |
JP7437558B1 (ja) | 2023-07-20 | 2024-02-22 | 株式会社ファーマフーズ | 情報処理装置、情報処理方法、およびプログラム |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4657760A (en) * | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4444887A (en) * | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4469863A (en) * | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) * | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
FI831484L (fi) | 1982-05-05 | 1983-11-06 | Genentech Inc | Plasminogen aktivator foer maenskovaevnad |
US4716111A (en) * | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4725576A (en) * | 1983-12-29 | 1988-02-16 | Research Foundation Of State University Of New York | Fungicidal polypeptide compositions containing L-histidine and methods for use therefore |
US4609725A (en) * | 1984-10-09 | 1986-09-02 | Merck & Co., Inc. | Cardiac atrial peptides |
ATE68013T1 (de) * | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5340934A (en) * | 1989-11-03 | 1994-08-23 | The United States Of Americas As Represented By The Secretary Of Health & Human Services | CDNA sequences of human bone matrix proteins |
US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
GB9216558D0 (en) | 1992-08-04 | 1992-09-16 | British Bio Technology | Modified proteases |
US6221645B1 (en) | 1995-06-07 | 2001-04-24 | Elan Pharmaceuticals, Inc. | β-secretase antibody |
US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
EP0871720A2 (fr) | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, anticorps diriges contre la beta-secretase et dosages permettant de detecter l'inhibition de la beta-secretase |
GB9701684D0 (en) | 1997-01-28 | 1997-03-19 | Smithkline Beecham Plc | Novel compounds |
AU9484398A (en) * | 1997-09-17 | 1999-04-05 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
WO1999031236A2 (fr) | 1997-12-17 | 1999-06-24 | Genset | ADNc PROLONGES POUR PROTEINES SECRETEES |
US20060009633A9 (en) * | 1997-11-13 | 2006-01-12 | Genset, S.A. | Complementary DNAs encoding proteins with signal peptides |
CA2315058A1 (fr) * | 1997-12-16 | 1999-06-24 | President And Fellows Of Harvard College | Mimetiques a coordonnees d'endostatine generes par ordinateur |
JP2002505097A (ja) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | 治療薬としてのcd147結合分子 |
JP2002511259A (ja) * | 1998-04-09 | 2002-04-16 | ジェンセット | 5’estおよびコードされるヒトタンパク質 |
US6184241B1 (en) | 1998-08-24 | 2001-02-06 | Kansas State University Research Foundation | Aspartic protease inhibitors |
CN1198936C (zh) | 1998-09-24 | 2005-04-27 | 法玛西雅厄普约翰美国公司 | 阿尔茨海默氏疾病分泌酶 |
WO2001053455A2 (fr) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides associes |
WO2000035473A2 (fr) * | 1998-12-18 | 2000-06-22 | Scios Inc. | Methodes de detection et d'utilisation de genes exprimes de façon differentielle dans des maladies |
EP1165609A2 (fr) | 1999-02-10 | 2002-01-02 | Elan Pharmaceuticals, Inc. | Compositions a base d'enzyme beta-secretase et procedes |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
AU3770800A (en) | 1999-03-26 | 2000-10-16 | Amgen, Inc. | Beta secretase genes and polypeptides |
DE19915485A1 (de) * | 1999-04-07 | 2000-10-19 | Hugo A Katus | Therapie der Herzinsuffizienz |
JP5138851B2 (ja) | 1999-06-28 | 2013-02-06 | オクラホマ メディカル リサーチ ファウンデーション | 触媒的に活性な組換えメマプシンおよびその使用方法 |
AU7058000A (en) * | 1999-08-13 | 2001-03-13 | Human Genome Sciences, Inc. | 13 human colon and colon cancer associated proteins |
EP1216258A1 (fr) * | 1999-09-28 | 2002-06-26 | Universität Zürich | Facteurs ayant une activite de liaison au prion dans du serum ou du plasma et agents permettant de detecter l'encephalopathie spongiforme transmissible |
WO2002000677A1 (fr) * | 2000-06-07 | 2002-01-03 | Human Genome Sciences, Inc. | Acides nucleiques, proteines et anticorps |
-
2001
- 2001-08-06 EP EP01965538A patent/EP1390497A2/fr not_active Withdrawn
- 2001-08-06 CA CA002448253A patent/CA2448253A1/fr not_active Abandoned
- 2001-08-06 AU AU2001286171A patent/AU2001286171B2/en not_active Ceased
- 2001-08-06 US US09/924,340 patent/US7074901B2/en not_active Expired - Fee Related
- 2001-08-06 IL IL15901501A patent/IL159015A0/xx unknown
- 2001-08-06 WO PCT/IB2001/001715 patent/WO2002094864A2/fr active Application Filing
- 2001-08-06 JP JP2002592338A patent/JP2005508141A/ja active Pending
- 2001-11-13 US US09/992,095 patent/US6989262B2/en not_active Expired - Fee Related
- 2001-11-13 US US09/992,600 patent/US7074571B2/en not_active Expired - Fee Related
- 2001-11-14 US US10/000,986 patent/US7005500B2/en not_active Expired - Fee Related
- 2001-11-14 US US10/001,142 patent/US7122629B2/en not_active Expired - Fee Related
- 2001-11-14 US US10/000,489 patent/US6794363B2/en not_active Expired - Fee Related
- 2001-11-14 US US09/999,570 patent/US7094876B2/en not_active Expired - Fee Related
-
2004
- 2004-05-03 US US10/838,854 patent/US7291495B2/en not_active Expired - Fee Related
-
2006
- 2006-04-27 US US11/412,325 patent/US20060211090A1/en not_active Abandoned
-
2007
- 2007-07-31 US US11/831,468 patent/US20070292885A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030096247A1 (en) | 2003-05-22 |
WO2002094864A3 (fr) | 2003-06-19 |
US20030198954A1 (en) | 2003-10-23 |
EP1390497A2 (fr) | 2004-02-25 |
US20030027161A1 (en) | 2003-02-06 |
US20030027248A1 (en) | 2003-02-06 |
AU2001286171B2 (en) | 2008-01-10 |
AU2001286171B8 (en) | 2002-12-03 |
US6794363B2 (en) | 2004-09-21 |
CA2448253A1 (fr) | 2002-11-28 |
US6989262B2 (en) | 2006-01-24 |
US20030170628A1 (en) | 2003-09-11 |
WO2002094864A2 (fr) | 2002-11-28 |
US7122629B2 (en) | 2006-10-17 |
US7074571B2 (en) | 2006-07-11 |
US7291495B2 (en) | 2007-11-06 |
US7005500B2 (en) | 2006-02-28 |
US20030092011A1 (en) | 2003-05-15 |
US20060211090A1 (en) | 2006-09-21 |
US20070292885A1 (en) | 2007-12-20 |
US20050026182A1 (en) | 2005-02-03 |
US7094876B2 (en) | 2006-08-22 |
JP2005508141A (ja) | 2005-03-31 |
US7074901B2 (en) | 2006-07-11 |
US20030157485A1 (en) | 2003-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL159015A0 (en) | Polypeptides, their preparation and use | |
HUP0500989A2 (en) | Animicrobial polypeptides and their uses | |
TWI371450B (en) | Novel substituted dihydro 3-halo-1h-pyrazole-5-carboxylates,their preparation and use | |
HUP0401335A3 (en) | Herbicidal pyridylpropynyloxyphenyl derivatives, preparation and use thereof | |
IL159275A0 (en) | Phenylsulfonyl-1, 3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | |
AU2002359126A8 (en) | Benzodiazepine derivatives, preparation thereof and use thereof | |
AU2002359123A8 (en) | Benzodiazepine derivatives, preparation thereof and use thereof | |
IL158397A0 (en) | Polypeptides, their preparation and their use | |
TWI318974B (en) | Acylaminothiazole derivatives, their preparation and their therapeutic use | |
HK1031725A1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and their use | |
HUP0401092A3 (en) | 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof | |
IL159872A0 (en) | Gmg-2 polypeptides and their use | |
HUP0401157A3 (en) | Methyl-thieno-benzodiazepine lyophilized formulation, its preparation and use | |
HUP0600238A2 (en) | Benzothiazole- and benzoxazole-4,7-dione derivatives and their use | |
PL365342A1 (en) | Mikanolide derivatives, their preparation and therapeutic uses | |
GB0217548D0 (en) | Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12 | |
SI1043306T1 (en) | 3-amino-3-arylpropan-1-ol-derivates, their preparation and use | |
IL158435A0 (en) | Polypeptides, derivatives and uses thereof | |
EP1248801A4 (fr) | Polynucleotides, polypeptides et anticorps humains | |
HK1065792A1 (en) | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino Ä4,5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use | |
EP1367123A4 (fr) | Neurotonine et utilisation | |
HUP0203678A3 (en) | Nitro-sulfobenzamide-derivatives, preparation and use thereof | |
GB0200843D0 (en) | Benzodioxinopyrroles their preparation and use | |
GB0106782D0 (en) | Polypeptides, methods and means | |
GB0030059D0 (en) | Polypeptides, methods and means |